GE HealthCare has announced the launch of Invenia Automated Breast Ultrasound (ABUS) Premium, the latest 3D ultrasound offering advanced Artificial Intelligence (AI) and innovative features to drive faster, reproducible supplemental screening and streamline exam readings on patients with dense breasts.
Approximately 71% of cancers occur in dense breasts. According to studies across the US and Europe, 40% of women and 70% of Asian women have dense breast tissue, making them four to six times more likely to receive a breast cancer diagnosis. Early detection of breast cancer is critical, yet about one-third of cancers in dense breasts may go undetected by a mammogram, as the cancer can be masked within the dense tissue. There is rapidly growing evidence supporting ABUS as a valuable tool for detecting cancer in dense breasts because it provides clearer and more detailed images and has been shown to improve the sensitivity of detecting invasive cancer in dense breasts when added to mammography.
“Women with dense breasts often face poorer outcomes due to malignancies detected at later, more advanced stages. Invenia ABUS Premium equipped with AI has the potential to optimise clinicians’ screening capabilities, enabling them to detect even small, early-stage cancers with a high degree of confidence in women with dense breasts,” said Karley Yoder, CEO of Comprehensive Care Ultrasound, GE HealthCare. “Invenia ABUS Premium is designed to help deliver the best possible outcomes for patients while also prioritising the patient experience with features to improve scan speed and enhance comfort during an exam.”
